QIAGEN N.V. today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V., to develop innovative bioinformatics and assay solutions to ....
Qiagen is launching three next-generation sequencing workflows for cancer research, expanding the clinical oncology footprint of the German company’s GeneReader platform.